How were BiondVax Pharmaceuticals' earnings last quarter?

BiondVax Pharmaceuticals Ltd. (NASDAQ:BVXV) issued its earnings results on Monday, March, 28th. The company reported ($2.70) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.90) by $1.80.

When did BiondVax Pharmaceuticals' stock split?

BiondVax Pharmaceuticals shares reverse split on the morning of Friday, November 25th 2022. The 1-10 reverse split was announced on Friday, November 25th 2022. The number of shares owned by shareholders was adjusted after the closing bell on Friday, November 25th 2022. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split.

What other stocks do shareholders of BiondVax Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other BiondVax Pharmaceuticals investors own include Gilead Sciences (GILD) , AbbVie (ABBV) , Pluristem Therapeutics (PSTI) , Exelixis (EXEL) , NVIDIA (NVDA) , Teva Pharmaceutical Industries (TEVA) , Adaptimmune Therapeutics (ADAP) , AVEO Pharmaceuticals (AVEO) , Anavex Life Sciences (AVXL) and Alibaba Group (BABA) .

When did BiondVax Pharmaceuticals IPO?

BiondVax Pharmaceuticals (BVXV) raised $10 million in an IPO on Tuesday, May 12th 2015. The company issued 1,400,000 shares at $7.32 per share. Aegis Capital Corp served as the underwriter for the IPO.

NASDAQ:BVXV

BiondVax Pharmaceuticals (BVXV) Stock Price, News & Analysis

→ The “Perfect Storm” for Gold (From Gold Safe Exchange) (Ad)

Free BVXV Stock Alerts

Notice: This company has been marked as potentially delisted and may not be actively trading.

Compare

Today's Range: N/A
50-Day Range: $1.26
▼
$1.59
52-Week Range: N/A

Volume: 23,000 shs
Average Volume: 127,289 shs
Market Capitalization: $2.54 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: N/A

Stock Analysis

Get BiondVax Pharmaceuticals alerts:

Ad Gold Safe Exchange

The “Perfect Storm” for Gold

Gold has already reached all-time highs, and experts believe it's not slowing down any time soon. In fact, some analysts predict a $7,000 price tag by 2025.

Click here now to download the free Precious Metals Buying Guide!

About BiondVax Pharmaceuticals Stock (NASDAQ:BVXV)

BiondVax Pharmaceuticals Ltd., a development stage biopharmaceutical company, focuses on developing, manufacturing, and commercializing products for the prevention and treatment of infectious and autoimmune diseases, and other illnesses in Israel. The company has licensing and collaboration agreement with Max Planck Society and University Medical Center Göttingen for the development and commercialization of COVID-19 nanosized antibody (NanoAb); and development and commercialization of NanoAbs for various other disease indications. The company was incorporated in 2003 and is headquartered in Jerusalem, Israel.

Ad Gold Safe Exchange

The “Perfect Storm” for Gold

Gold has already reached all-time highs, and experts believe it's not slowing down any time soon. In fact, some analysts predict a $7,000 price tag by 2025.

Click here now to download the free Precious Metals Buying Guide!

BVXV Stock News Headlines

March 23, 2024 | seekingalpha.com

SCNI Scinai Immunotherapeutics Ltd.

October 4, 2023 | finance.yahoo.com

Scinai Immunotherapeutics to Showcase its end-to-end cGMP Biologics CDMO Services at CPHI Barcelona 2023

April 19, 2024 | Gold Safe Exchange (Ad)

The “Perfect Storm” for Gold

Gold has already reached all-time highs, and experts believe it's not slowing down any time soon. In fact, some analysts predict a $7,000 price tag by 2025.

September 19, 2023 | finance.yahoo.com

Scinai Immunotherapeutics Announces Closing of $1.33 Million Registered Direct Offering

September 15, 2023 | finance.yahoo.com

Scinai Immunotherapeutics Announces $1.33 Million Registered Direct Offering

September 13, 2023 | finance.yahoo.com

Scinai Immunotherapeutics Innovative Plaque Psoriasis Treatment Shows Encouraging Preclinical Results

September 11, 2023 | finance.yahoo.com

Scinai Immunotherapeutics Ltd. to participate this week in H.C. Wainwright 25th Annual Global Investment Conference in New York and LSX USA Congress 2023 in Boston

September 6, 2023 | financialpost.com

BiondVax Pharmaceuticals Ltd. Rebrands as Scinai Immunotherapeutics Ltd. to Reflect New Focus on Development of Novel Inflammation and Immunology (I&I) Biological Therapeutics

April 19, 2024 | Gold Safe Exchange (Ad)

The “Perfect Storm” for Gold

Gold has already reached all-time highs, and experts believe it's not slowing down any time soon. In fact, some analysts predict a $7,000 price tag by 2025.

August 11, 2023 | finanznachrichten.de

BiondVax Pharmaceuticals Ltd.: BiondVax Reports Second Quarter Financial Results and Provides Business Update

August 11, 2023 | finance.yahoo.com

BiondVax Reports Second Quarter Financial Results and Provides Business Update

August 2, 2023 | finanznachrichten.de

BiondVax Pharmaceuticals Ltd.: Nasdaq Grants BiondVax Extension to Regain Compliance with Listing Rules

August 1, 2023 | finance.yahoo.com

Nasdaq Grants BiondVax Extension to Regain Compliance with Listing Rules

July 28, 2023 | theglobeandmail.com

BiondVax (NASDAQ: BVXV) Leveraging NanoAb Pipeline to Target Large Markets

July 11, 2023 | finance.yahoo.com

IBN Announces Latest Episode of The Bell2Bell Podcast featuring Amir Reichman, CEO of BiondVax Pharmaceuticals Ltd.

July 6, 2023 | finance.yahoo.com

BVXV - BiondVax Pharmaceuticals Ltd.

June 5, 2023 | finance.yahoo.com

BiondVax signs exclusive license agreement for development and commercialization of a novel anti-IL-17 antibody for treatment of autoimmune and inflammatory diseases including psoriasis

May 30, 2023 | finance.yahoo.com

BVXV: Developing anti-IL-17 NanoAb

May 15, 2023 | finanznachrichten.de

BiondVax Pharmaceuticals Ltd.: BiondVax Announces First Quarter 2023 Financial Results and Provides Business Update

May 15, 2023 | msn.com

Biondvax Pharmaceuticals GAAP EPS of $0.00 beats by $0.73

May 15, 2023 | finance.yahoo.com

BiondVax Announces First Quarter 2023 Financial Results and Provides Business Update

April 20, 2023 | theglobeandmail.com

BiondVax Pharmaceuticals (NASDAQ: BVXV) Leads Biotechnology Frontier with Experienced Leadership Team

April 18, 2023 | finanznachrichten.de

BiondVax Pharmaceuticals Ltd.: BiondVax Files FY 2022 Financial Statements and Annual Report on Form 10-K and Provides Business Update

April 4, 2023 | marketwatch.com

BioMedNewsBreaks - BiondVax Pharmaceuticals Ltd.'s (NASDAQ: BVXV) Lead NanoAb Candidate Holds Significant Advantages to Existing Therapies

March 26, 2023 | marketwatch.com

BioMedNewsBreaks - BiondVax Pharmaceuticals Ltd.'s (NASDAQ: BVXV) NanoAb Holds Potential to Combat New COVID-19 Variants

March 16, 2023 | finance.yahoo.com

BiondVax to Present at BIO-Europe Spring

March 6, 2023 | finance.yahoo.com

IBN Highlights 'Test. Optimize. Scale.' Episode Featuring BiondVax Pharmaceuticals Ltd. CEO Amir Reichman

See More Headlines

Receive BVXV Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for BiondVax Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 3/28/2022
Today: 4/19/2024
Fiscal Year End: 12/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Biotechnology
Sub-Industry: N/A
Current Symbol: NASDAQ:BVXV
CUSIP: N/A
CIK: 1611747
Web: www.biondvax.com
Phone: 9723029302529
Fax: 972-8930-2531
Employees: 33
Year Founded: N/A

Profitability

EPS (Most Recent Fiscal Year): ($2.55)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-5,800,000.00
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: -346.36%
Return on Assets: -29.52%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 4.12
Quick Ratio: 4.12

Sales & Book Value

Annual Sales: N/A
Price / Sales: N/A
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: ($3.81) per share
Price / Book: N/A

Miscellaneous

Outstanding Shares: 1,870,000
Free Float: 1,755,000
Market Cap: $2.54 million
Optionable: Not Optionable
Beta: 2.37

Beginners Guide To Retirement Stocks

Click the link below and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.

Get This Free Report

Key Executives

Mr. Amir Reichman M.B.A. (Age 47)
M.Sc., CEO & Director
Comp: $562.5k
Mr. Elad Mark B.Sc. (Age 41)
Eng., M.B.A., Chief Operating Officer
Comp: $277.02k
Dr. Tamar Ben-Yedidia Ph.D. (Age 59)
Chief Science Officer
Comp: $314.92k
Mr. Uri Ben-Or CPA (Age 53)
CPA, M.B.A., MBA, Chief Financial Officer
Mr. Joshua E. Phillipson B.Sc.
M.B.A., Director of Communications & Investor Relations
Ms. Moran Ahdout Fruchter L.L.B.
Chief of Staff
Ms. Dalit Weinstein Fischer
VP and Head of Technical R&D

Key Competitors

View All Competitors

BVXV Stock Analysis - Frequently Asked Questions

How were BiondVax Pharmaceuticals' earnings last quarter?: BiondVax Pharmaceuticals Ltd. (NASDAQ:BVXV) issued its earnings results on Monday, March, 28th. The company reported ($2.70) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.90) by $1.80.
When did BiondVax Pharmaceuticals' stock split?: BiondVax Pharmaceuticals shares reverse split on the morning of Friday, November 25th 2022. The 1-10 reverse split was announced on Friday, November 25th 2022. The number of shares owned by shareholders was adjusted after the closing bell on Friday, November 25th 2022. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split.
What other stocks do shareholders of BiondVax Pharmaceuticals own?: Based on aggregate information from My MarketBeat watchlists, some companies that other BiondVax Pharmaceuticals investors own include Gilead Sciences (GILD), AbbVie (ABBV), Pluristem Therapeutics (PSTI), Exelixis (EXEL), NVIDIA (NVDA), Teva Pharmaceutical Industries (TEVA), Adaptimmune Therapeutics (ADAP), AVEO Pharmaceuticals (AVEO), Anavex Life Sciences (AVXL) and Alibaba Group (BABA).
When did BiondVax Pharmaceuticals IPO?: BiondVax Pharmaceuticals (BVXV) raised $10 million in an IPO on Tuesday, May 12th 2015. The company issued 1,400,000 shares at $7.32 per share. Aegis Capital Corp served as the underwriter for the IPO.

This page (NASDAQ:BVXV) was last updated on 4/19/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

BiondVax Pharmaceuticals (BVXV) Stock Price, News & Analysis

About BiondVax Pharmaceuticals Stock (NASDAQ:BVXV)

BVXV Stock News Headlines

Company Calendar

Industry, Sector and Symbol

Profitability

Debt

Sales & Book Value

Miscellaneous

Key Executives

Key Competitors

BVXV Stock Analysis - Frequently Asked Questions

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info